

Application No. : 10/655,532
Amdt. Dated : November 12, 2004
Reply To O.A. Of : August 11, 2004

AMENDMENTS TO THE CLAIMS

The listing of claims replaces all prior versions and listings of claims in the application. The listing of claims presents each claim with its respective status shown in parentheses.

1-41. [**Canceled**]

42. [**Currently Amended**] A drug delivery stent comprising:

- a stent structure configured to carry a plurality of therapeutic agents[.];
- at least a first therapeutic agent;
- at least a second therapeutic agent; and
- at least a third therapeutic agent,

wherein said first therapeutic agent is an anti-inflammatory, and wherein said second therapeutic agent and said third therapeutic agent are alternately provided repeatedly.

43. [**Original**] A drug-delivery stent comprising:

- an expandable tubular structure;
- at least a first drug, wherein said first drug is an anti-inflammatory;
- at least a second drug, wherein said second drug inhibits growth factor and cytokine-stimulated cell proliferation; and
- at least a third drug, wherein said third drug induces G1 cycle arrest in smooth muscle cells in-vitro and inhibits mitosis and neointimal formation in-vivo.

44. [**Original**] A method for treating a stenosed body lumen, comprising:

- delivering a stent to the body lumen; and
- delivering at least three drugs to the patient via said stent,

wherein at least one drug is an anti-inflammatory, and wherein at least one drug is provided repeatedly.

45. [**Original**] The method of Claim 44, wherein at least two drugs are provided alternately.

46. [**Original**] The method of Claim 45, wherein at least two drugs are alternately provided repeatedly.

Application No. : 10/655,532
Amdt. Dated : November 12, 2004
Reply To O.A. Of : August 11, 2004

47. **[Original]** A method for treating a stenosed body lumen, comprising:
delivering a stent to the body lumen; and
delivering at least three therapeutic agents to the patient via said stent,
wherein said at least three therapeutic agents are administered separately, and
wherein at least two therapeutic agents are alternately provided repeatedly.
48. **[New]** The stent of Claim 42, further comprising at least one polymer barrier layer comprising a drug.
49. **[New]** The stent of Claim 42, wherein the first therapeutic agent comprises a Corticosteroid.
50. **[New]** The stent of Claim 49, wherein the first therapeutic agent comprises Dexamethasone.
51. **[New]** The stent of Claim 42, wherein the second therapeutic agent comprises Sirolimus and mycophenolic acid.
52. **[New]** The stent of Claim 51, wherein Sirolimus comprises Rapamycin.
53. **[New]** The stent of Claim 42, wherein the third therapeutic agent comprises Paclitaxel.
54. **[New]** The stent of Claim 53, wherein the third therapeutic agent comprises Taxol.
55. **[New]** The stent of Claim 42, wherein the first therapeutic agent is selected from the group consisting of Clobetasone, Methyl Prednisolone, and Indomethacin, and combinations thereof.
56. **[New]** The stent of Claim 42, wherein the second therapeutic agent is selected from the group consisting of Tacrolimus, Everolimus, Antinomycin D, Adriamycin, Bleomycin A and B with Cisplatin, Bleomycin A and B without Cisplatin, an anti-proliferative agent, an anti-thrombogenic, heparin, and combinations thereof.
57. **[New]** The stent of Claim 42, wherein the third therapeutic agent is selected from the group consisting of Tacrolimus, Everolimus, Antinomycin D, Adriamycin, Bleomycin A and B with Cisplatin, Bleomycin A and B without Cisplatin, an anti-proliferative agent, an anti-thrombogenic, heparin, and combinations thereof.

Application No. : 10/655,532
Amdt. Dated : November 12, 2004
Reply To O.A. Of : August 11, 2004

58. **[New]** The stent of Claim 42, further comprising a polymer barrier layer selected from the group consisting of polyglycolic/polyactic acid copolymers, polycaprolactone, polyhydroxybutyrate/valerate copolymer, polyorthoester and polyethyleneoxide/polybutylene terephthalate copolymer, and combinations thereof.

59. **[New]** The stent of Claim 42, further comprising a polymer barrier layer that is biodegradable.

60. **[New]** The stent of Claim 48, wherein the therapeutic agent is dispensed as a mixture, micronized, microspheres, and combinations thereof.

61. **[New]** The stent of Claim 42, wherein a diameter of a proximal end of the stent and a diameter of a distal end of the stent are greater than a diameter of a center portion of the stent.

62. **[New]** The stent of Claim 42, wherein the stent, in use, is long enough such that a distal end and a proximal end of the stent each extend about 1-6mm beyond a stenosis.

63. **[New]** The stent of Claim 42, wherein, in use, a distal end and a proximal end of the stent each extend about 5mm beyond a stenosis.

64. **[New]** The stent of Claim 42, wherein, in use, a distal end and a proximal end of the stent each extend at least 1mm beyond a stenosis.

65. **[New]** The stent of Claim 42, wherein the stent is self-expanding.

66. **[New]** The stent of Claim 42, wherein the stent is expanded by a balloon.

67. **[New]** The stent of Claim 42, wherein at least one of the therapeutic agents is a time-released drug.

68. **[New]** The stent of Claim 42, wherein a diameter of a proximal end of the stent is equal to a diameter of a distal end of the stent.

69. **[New]** The stent of Claim 42, wherein a diameter of a proximal end of the stent is greater than a diameter of a distal end of the stent.

Application No. : 10/655,532
Amdt. Dated : November 12, 2004
Reply To O.A. Of : August 11, 2004

70. **[New]** A stent comprising:

- a tubular member having a proximal end, a distal end, and a center portion;

- a first drug layer;

- a polymer barrier layer between the first drug layer and the tubular member;

- a second drug layer;

- a polymer barrier layer between the first drug layer and the second drug layer;

- a third drug layer;

- a polymer barrier layer between the second drug layer and third drug layer;

- a fourth drug layer;

- a polymer barrier layer between the third drug layer and the fourth drug layer;

- a fifth drug layer; and

- a polymer barrier layer between the fourth drug layer and the fifth drug layer;

- wherein at least one of the polymer barrier layers comprise a drug.

71. **[New]** The stent of Claim 70, wherein the second drug layer and fourth drug layer comprise the same drug.

72. **[New]** The stent of Claim 70, wherein the third and fifth drug layers comprise the same drug.

73. **[New]** The stent of Claim 70, wherein at least two of the first, second, third, fourth, and fifth drug layers comprise the same drug.